Peter Abair

Special To Banker & Tradesman

Peter Abair is director of economic development and global affairs at the Massachusetts Biotechnology Council (MassBio).
Peter Abair can be reached at editorial@thewarrengroup.com
Alexandria Real Estate’s Triumphant Year

Alexandria Real Estate’s Triumphant Year

Rather than the ubiquitous “2015 retrospective,” in this week’s column, I offer instead a winner’s circle. In 2015, it’s tough to think about a loser in the life sciences real estate space. It was an incredible year, built upon the wonderful preceding year. If there...

Massachusetts Needs To Connect On Biomanufacturing Prospects

As baseball’s World Series nears, we note that Massachusetts has had two swings at the plate without connecting in the 2015 global site selection contest for large biopharmaceutical manufacturing facilities. I’ve noted in past columns that Massachusetts is strong in...

Investment In Biotech Remains Hot

  After a record 2014, in which Massachusetts biotechs set records in amount of venture capital received and number of IPOs, the local industry remains red-hot in 2015. Through July, 33 Massachusetts biotechs had received $889 million in VC financing and nine...

Massachusetts Life Sciences: A Winning Pick

Over the past decade, the biopharmaceutical industry has grown by 40 percent in Massachusetts, reaching 58,000 employees and contributing over $7 billion in Massachusetts-based payroll in 2013.  It’s a great story.  Biotech is a homegrown industry, with a strong...

King Street Shines A Light On Suburban Lab Market

Back in the day, pioneers in the development of commercial laboratory space, such as David Klem of the old Athenaeum Group and Lyme Properties and Bill Cummings, had to be smart, had to take on risk, and had to be very patient with biotech industry of the 1980s and...

AbbVie-Shire Deal Likely To Strengthen Mass. Biotech Scene

Mergers are nothing new in the drug development industry, but when two companies with substantial operations locally are involved, it’s worthy of note. In mid-July, drug-maker AbbVie announced it would acquire Shire Pharmaceuticals for $54 billion. It’s the biggest acquisition of the year.

Four Fathers And The March Toward Cures

Two weeks ago, 15,000 people from around the world gathered at the annual BIO International Convention in San Diego. BIO was a four-day affair that included hundreds of panel discussion, tens of thousands of business partnering meetings, an exhibition hall with hundreds of companies, state and national exhibits, pavilions and not a few receptions. With the whirlwind of activity, it can be difficult to discern what should be the central focus of such a convention – the patient.

Virtual Companies Are Here To Stay

Time is money. That’s true in any industry. In the biopharmaceutical industry, it is estimated that it takes 10 years to research and develop a commercial drug product. A mid-range estimate of the average development cost for an approved drug product is $1 billion.

Looking Back At Education Reform

As we near the end of 2013, it is an appropriate time to mark the 20th anniversary of the passage of the Education Reform Act of 1993. With 20 years of dramatically improved academic performance in our Massachusetts public schools, we can say unequivocally that education reform has been a success.

Cambridge’s Net-Zero Proposal Could Be Setback

Boston and Cambridge have taken significant steps this year toward developing thoughtful public policy approaches to developing and implementing clean energy practices. The Cambridge Compact for a Sustainable Future is a city-, Harvard- and MIT-led effort to engage stakeholders across the private-public spectrum to recommend policy initiatives on issues from energy efficiency and renewable energy to storm water management.

Argeo Paul Cellucci, 1948-2013

Beginning in 1997, I served as the director of Gov. Paul Cellucci’s office in western Massachusetts. Operating at a distant outpost of the administration in Springfield, I repeatedly benefitted from Paul Cellucci’s interest in the state’s western four counties. During the year and a half (prior to his election in 1998) that the media insisted on addressing Cellucci as “acting governor,” he visited western Massachusetts 24 times, an unprecedented number of visits for a sitting governor. Paul Cellucci, hailing from his native Hudson, knew well the perception among those in communities and regions west of Route 128 that Beacon Hill considered their interests and struggles rarely. I can recall one political strategist, noting the comparatively few votes to be had in western Massachusetts, saying there was little political need for statewide office holders to spend any time in western Massachusetts. Paul Cellucci would have none of that. He was engaged in the issues affecting that region and those in every Massachusetts region.